Threat Intelligence Sharing Platforms: An Exploratory Study of Software Vendors and Research Perspectives

In the last couple of years, organizations have demonstrated an increased willingness to exchange information and knowledge regarding vulnerabilities, threats, incidents and mitigation strategies in order to collectively protect against today’s sophisticated cyberattacks. As a reaction to this trend, software vendors started to create offerings that facilitate this exchange and appear under the umbrella term “Threat Intelligence Sharing Platforms”. To which extent these platforms provide the needed means for exchange and information sharing remains unclear as they lack a common definition, innovation in this area is mostly driven by vendors and empirical research is rare. To close this gap, we examine the state-of-the-art software vendor landscape of these platforms, identify gaps and present arising research perspectives. Therefore, we conducted a systematic study of 22 threat intelligence sharing platforms and compared them. We derived eight key findings and discuss how existing gaps should be addressed by future research

Towards an Evaluation Framework for Threat Intelligence Sharing Platforms

Threat intelligence sharing is an important countermeasure against the increasing number of security threats to which companies and governments are exposed. Its objective is the cross-organizational exchange of information about actual and potential threats. In recent years, a heterogeneous market of threat intelligence sharing platforms (TISPs) has emerged. These platforms are inter-organizational systems that support collaborative collection, aggregation, analysis and dissemination of threat-related information. Organizations that consider using TISPs are often faced with the challenge of selecting suitable platforms. To facilitate the evaluation of threat intelligence sharing platforms, we present a framework for analyzing and comparing relevant TISPs. Our framework provides a set of 25 functional and non-functional criteria that support potential users in selecting suitable platforms. We demonstrate the applicability of our evaluation framework by assessing three platforms: MISP, OTX and ThreatQ. We describe common features and differences between the three platforms

Lecturers’ and Students’ Experiences with an Automated Programming Assessment System

Assessment of source code in university education has become an integral part of grading students and providing them valuable feedback on their developed software solutions. Thereby, lecturers have to deal with a rapidly growing number of students from heterogeneous fields of study, a shortage of lecturers, a highly dynamic set of learning objectives and technologies, and the need for more targeted student support. To meet these challenges, the use of an automated programming assessment system (APAS) to support traditional teaching is a promising solution. This paper examines this trend by analyzing the experiences of lecturers and students at various universities with an APAS and its impact over the course of a semester. In doing so, we conducted a total number of 30 expert interviews with end users, including 15 lecturers and 15 students, from four different universities within the same country. The results discuss the experiences of lecturers and students and highlight challenges that should be addressed in future research

CodeAbility Austria – Digital gestützte Programmierausbildung an österreichischen Universitäten

Qualitativ hochwertige Programmierausbildung an Universitäten stellt aufgrund von stark steigenden Zahlen von Studierenden, knapp bemessenen Lehrebudgets und Mangel an Lehrkräften eine große Herausforderung dar. Ziel des Projekts „CodeAbility Austria“ ist es, diesen universitären Rahmenbedingungen gerecht zu werden und Programmierlernplattformen bereitzustellen. Im Rahmen dieses Beitrags stellen wir das Projekt näher vor, präsentieren Ergebnisse unserer empirischen Untersuchungen hinsichtlich der Erfahrungen und Herausforderungen im Umgang mit Programmierlernplattformen in der universitären Lehre und geben einen Ausblick auf zukünftige Arbeiten. Dieses Projekt wurde am 1. Juni 2023 im Rahmen einer Online-Veranstaltung des BMBWF präsentiert. Die Präsentationsunterlagen finden Sie hier

Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty.

BACKGROUND: Beta radiation is effective in reducing vascular neointimal proliferation in animals after injury caused by balloon angioplasty. However, the lowest dose that can prevent restenosis after coronary angioplasty has yet to be determined. METHODS: After successful balloon angioplasty of a previously untreated coronary stenosis, 181 patients were randomly assigned to receive 9, 12, 15, or 18 Gy of radiation delivered by a centered yttrium-90 source. Adjunctive stenting was required in 28 percent of the patients. The primary end point was the minimal luminal diameter six months after treatment, as a function of the delivered dose of radiation. RESULTS: At the time of follow-up coronary angiography, the mean minimal luminal diameter was 1.67 mm in the 9-Gy group, 1.76 mm in the 12-Gy group, 1.83 mm in the 15-Gy group, and 1.97 mm in the 18-Gy group (P=0.06 for the comparison of 9 Gy with 18 Gy), resulting in restenosis rates of 29 percent, 21 percent, 16 percent, and 15 percent, respectively (P=0.14 for the comparison of 9 Gy with 18 Gy). At that time, 86 percent of the patients had had no serious cardiac events. In 130 patients treated with balloon angioplasty alone, restenosis rates were 28 percent, 17 percent, 16 percent, and 4 percent, respectively (P=0.02 for the comparison of 9 Gy with 18 Gy). Among these patients, there was a dose-dependent enlargement of the lumen in 28 percent, 50 percent, 45 percent, and 74 percent of patients, respectively (P<0.001 for the comparison of 9 Gy with 18 Gy). The rate of repeated revascularization was 18 percent with 9 Gy and 6 percent with 18 Gy (P=0.26). CONCLUSIONS: Intracoronary beta radiation therapy produces a significant dose-dependent decrease in the rate of restenosis after angioplasty. An 18-Gy dose not only prevents the renarrowing of the lumen typically observed after successful balloon angioplasty, but actually induces luminal enlargement

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.

Preventing relapses of Plasmodium vivax malaria through a radical cure depends on use of the 8-aminoquinoline primaquine, which is associated with safety and compliance issues. For future malaria eradication strategies, new, safer radical curative compounds that efficiently kill dormant liver stages (hypnozoites) will be essential. A new compound with potential radical cure activity was identified using a low-throughput assay of in vitro-cultured hypnozoite forms of Plasmodium cynomolgi (an excellent and accessible model for Plasmodium vivax). In this assay, primary rhesus hepatocytes are infected with P. cynomolgi sporozoites, and exoerythrocytic development is monitored in the presence of compounds. Liver stage cultures are fixed after 6 days and stained with anti-Hsp70 antibodies, and the relative proportions of small (hypnozoite) and large (schizont) forms relative to the untreated controls are determined. This assay was used to screen a series of 18 known antimalarials and 14 new non-8-aminoquinolines (preselected for blood and/or liver stage activity) in three-point 10-fold dilutions (0.1, 1, and 10 μM final concentrations). A novel compound, designated KAI407 showed an activity profile similar to that of primaquine (PQ), efficiently killing the earliest stages of the parasites that become either primary hepatic schizonts or hypnozoites (50% inhibitory concentration [IC50] for hypnozoites, KAI407, 0.69 μM, and PQ, 0.84 μM; for developing liver stages, KAI407, 0.64 μM, and PQ, 0.37 μM). When given as causal prophylaxis, a single oral dose of 100 mg/kg of body weight prevented blood stage parasitemia in mice. From these results, we conclude that KAI407 may represent a new compound class for P. vivax malaria prophylaxis and potentially a radical cure

Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery

Contains fulltext : 96475.pdf (publisher's version ) (Open Access)BACKGROUND: Amongst the Plasmodium species in humans, only P. vivax and P. ovale produce latent hepatic stages called hypnozoites, which are responsible for malaria episodes long after a mosquito bite. Relapses contribute to increased morbidity, and complicate malaria elimination programs. A single drug effective against hypnozoites, primaquine, is available, but its deployment is curtailed by its haemolytic potential in glucose-6-phosphate dehydrogenase deficient persons. Novel compounds are thus urgently needed to replace primaquine. Discovery of compounds active against hypnozoites is restricted to the in vivo P. cynomolgi-rhesus monkey model. Slow growing hepatic parasites reminiscent of hypnozoites had been noted in cultured P. vivax-infected hepatoma cells, but similar forms are also observed in vitro by other species including P. falciparum that do not produce hypnozoites. METHODOLOGY: P. falciparum or P. cynomolgi sporozoites were used to infect human or Macaca fascicularis primary hepatocytes, respectively. The susceptibility of the slow and normally growing hepatic forms obtained in vitro to three antimalarial drugs, one active against hepatic forms including hypnozoites and two only against the growing forms, was measured. RESULTS: The non-dividing slow growing P. cynomolgi hepatic forms, observed in vitro in primary hepatocytes from the natural host Macaca fascicularis, can be distinguished from similar forms seen in P. falciparum-infected human primary hepatocytes by the differential action of selected anti-malarial drugs. Whereas atovaquone and pyrimethamine are active on all the dividing hepatic forms observed, the P. cynomolgi slow growing forms are highly resistant to treatment by these drugs, but remain susceptible to primaquine. CONCLUSION: Resistance of the non-dividing P. cynomolgi forms to atovaquone and pyrimethamine, which do not prevent relapses, strongly suggests that these slow growing forms are hypnozoites. This represents a first step towards the development of a practical medium-throughput in vitro screening assay for novel hypnozoiticidal drugs